The company's lower P/E ratio is due to its poor earnings outlook. Investors feel that the potential for earnings improvement doesn't justify a higher P/E ratio. This sentiment may continue to affect the share price unless conditions improve.

Despite a 25% share-value drop for the year, Pulike Biological Engineering's overall gain of 14% p.a over half a decade along with its consistent growth trend, commands market respect. Current sell-off could be a potential opportunity if the trend continues.